semaglutide prediabetes progression to type 2 diabetes trial once a week in adults with overweight or obesity, with or without in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a SELECT Trial

The events at ARDD2025 have sparked urgent discussions among R&D leaders, all grappling with the same fundamental questions: What is the best way to discover and develop longevity therapeutics that will follow the GLP-1 story

The net impact on glucose homeostasis is small, but patients with prediabetes or insulin resistance should have fasting glucose and HbA1c checked within 30 days of starting both medications

However, side effects nausea, vomiting, and diarrhea typically resolve by month 3 for both medications

Take Control of Your Weight Today Weight loss doesnt need to revolve around clinic visits or complicated schedules

This equates to approximately 0.73mcg/lb, or about 146mcg for an individual weighing 200lb

The drug did not meaningfully slow down the diseases progression compared to placebo, the trials showed